Search Results for: Global Cancer Vaccine Market to
Articles
SPECIAL FEATURE - Formulation Development & Manufacturing - CDMOs Offer Speed, Advanced Technologies, & the Ability to Handle More Potent APIs April 4, 2017
Contributor Cindy H. Dubin speaks with some of the industry’s leading CDMOs to highlight their capabilities in the areas of speed, quality, technology, and handling of complex APIs.
EXECUTIVE INTERVIEW - Vetter: Establishing a Successful Clinical Fill & Finish Manufacturing Site for Biologics April 3, 2017
Dr. Susanne Resatz, President of Vetter Development Services USA, Inc., discusses the many benefits to small biotech companies in utilizing the services of a full-service CDMO, and what advanced services the Chicago-based facility offers its growing customer base.
Catalent Biologics Announces Agreement With Moderna Therapeutics October 13, 2016
Catalent Pharma Solutions, a leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health...SPECIAL FEATURE - Platform Technologies: Not Just for Big Pharma October 3, 2016
Contributor Cindy H. Dubin recently spoke with several companies that are debunking the theory that access to the latest technological platforms to aid efficient drug discovery and development is limited to Big Pharma, which can more easily justify the costs of creating and operating innovative platforms.
Cellular Immunotherapies Represent Long-Term Opportunity in Immuno-Oncology Space May 9, 2016
While cellular immunotherapies, which encompass dendritic cell therapy and chimeric antigen receptor T-cell (CAR-T) therapy, are expected to show promising...BioXcel Strengthens Position in Immuno-Oncology With Dedicated Big Data Analytics Platform January 26, 2016
BioXcel Corporation recently announced the launch of its first in class PharmGPS Oncology and Immuno-Oncology Suite. The platform’s comprehensive big...EXECUTIVE INTERVIEW - Capsugel: Choosing the Right Pharmaceutical Design, Development & Manufacturing Partner January 7, 2016
Pharmaceutical companies today increasingly require specialized design, development, and manufacturing partners to help bring new and improved drugs to market....Ergomed Significantly Increases Contribution in CEL-SCI’s Phase III Trial October 8, 2015
CEL-SCI Corporation and its Clinical Research Organization (CRO) Ergomed plc recently announced they have expanded their co-development agreement with increased...EXECUTIVE INTERVIEW - Vetter: Helping Small Biotech Companies Execute a Successful Drug Development Process October 5, 2015
Dr. Susanne Resatz, President of Vetter Development Services USA, Inc., discusses the many benefits to small biotech companies in utilizing a full-service CDMO, and what advanced services the Chicago-based facility offers its growing customer base.
US Patent Granted for Use of Genticel’s Antigen Delivery Vectors September 12, 2015
Genticel recently announced that a new patent (No. 9,095,537), Therapy of Cancer Based on Targeting Adaptive, Innate and/or Regulatory...MorphoSys & Immatics Biotechnologies Enter Strategic Alliance August 31, 2015
MorphoSys AG and Immatics Biotechnologies GmbH recently announced a strategic alliance to generate novel antibody-based therapeutics against multiple proprietary cancer...Selecta Biosciences Makes Two Major Announcements May 18, 2015
Selecta Biosciences, Inc. recently announced that, under the terms of an existing strategic global collaboration, Sanofi has exercised its option...Sanofi & MannKind Announce Afrezza, the Only Inhaled Insulin, Now Available in the US February 4, 2015
Sanofi and MannKind Corporation announced today that Afrezza® (insulin human) Inhalation Powder, the only inhaled insulin, is now available by...Frost & Sullivan Releases Drug Launch Phase III Trial Watch List for Top Therapeutic Areas January 13, 2015
The therapeutics market is buzzing with activity, as several promising therapies are progressing to Phase III clinical trials and many...Top 30 Pharma Companies Spent $112 Billion on Research & Development in 2013 December 16, 2014
LONDON, UK (GlobalData), 16 December 2014 - The world’s leading 30 pharmaceutical companies spent a combined $112 billion on research...Boehringer Ingelheim & CureVac Announce Major Development Collaboration September 22, 2014
Boehringer Ingelheim and CureVac recently announced an exclusive global license and development collaboration. The new collaboration focuses on CureVac’s CV9202,...FIXED-DOSE COMBINATIONS - Fixed-Dose Combination Products - What’s in the Clinic? (Part 3 – Pipeline) May 7, 2014
Tugrul T. Kararli, PhD, MBA; Kurt Sedo; and Josef Bossart, PhD, believe the pharmaceutical industry has been paying increasing attention to the potential of Fixed-Dose Combination products, and conclude this series of three articles, examining the past, present, and future of these products with the intent of understanding their whats and whys.
Are Mega M&As Back in Pharma? April 28, 2014
According to Frost & Sullivan, the pharmaceutical industry is witnessing a new wave of mergers and acquisitions activities, especially mega...Merck Plans Radical Overhaul of R&D Unit January 7, 2014
Merck & Co. Inc. is working on a plan to radically reshape its once-storied R&D unit that would create international...INTRADERMAL DELIVERY - Advances in Intradermal Drug Delivery October 16, 2013
Zach Marks, MS, RPh, believes efficiency of vaccine use will be critical as the world population continues to grow and vaccine prices continue to rise, and ID administration can help reduce dose cost while potentially improving immunogenicity in traditional and hard-to-treat populations.
